Carisma Therapeutics Inc.

73 articles about Carisma Therapeutics Inc.

• Carisma Therapeutics to Present at Upcoming Investor Conferences

  9/5/2023

  Carisma Therapeutics Inc. today announced that it will present at several upcoming investor conferences.

• Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

  9/1/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will present findings today at the 8th Annual CAR-TCR Summit from its Phase 1 clinical trial of the Company's lead product candidate, CT-0508.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

  8/24/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023.

• Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

  8/10/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2023, and highlighted recent business updates.

• Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

  6/28/2023

  Carisma Therapeutics Inc. announced that the first patient has been dosed in its Phase I clinical trial that will test the safety and tolerability of the Company's lead product candidate, CT-0508.

• Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes

  6/26/2023

  Carisma Therapeutics Inc. today announced that the Company will join the Russell 2000 ® , Russell 3000 ® and Russell Microcap ® Indexes following the conclusion of the 2023 Russell indexes annual reconstitution, effective upon the U.S. markets open today, June 26, 2023.

• Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources

  6/14/2023

  Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates.

• Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023

  6/5/2023

  Carisma Therapeutics Inc. today announced that the Company will present at several investor conferences in June 2023.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

  5/30/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023.

• Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

  5/11/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.

• Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference - May 08, 2023

  5/8/2023

  Carisma Therapeutics Inc. announced that Steven Kelly, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 1:00 pm EDT in New York.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023

  5/5/2023

  Carisma Therapeutics Inc. today announced that the company will present at several healthcare industry conferences in May 2023.

• Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting

  4/14/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced three abstracts were accepted for presentation at The American Association for Cancer Research (AACR) Annual Meeting held from Friday, April 14 – Wednesday, April 19 in Orlando, FL.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023

  4/6/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will participate at several conferences in April 2023.

• Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights

  4/4/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the year ended December 31, 2022 and highlighted recent business updates.

• Carisma Therapeutics Closes Merger with Sesen Bio

  3/7/2023

  Carisma Therapeutics Inc. and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger.

• Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

  3/2/2023

  Sesen Bio, Inc., announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc., at the Company’s Special Meeting of Stockholders.

• Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

  2/16/2023

  Sesen Bio, Inc. announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. management team on Tuesday, February 21, 2023, at 8:00 am ET.

• BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

  2/15/2023

  Sesen Bio, Inc., announced that BML Investment Partners, L.P., one of Sesen Bio’s top stockholders, intends to vote all of its shares in support of the Company’s pending merger with Carisma Therapeutics Inc.

• Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger

  2/14/2023

  Sesen Bio, Inc. and Carisma Therapeutics Inc. announced that the companies have reached a voting and support agreement with Bradley L. Radoff and Michael Torok.